Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$76.44 USD

76.44
7,419,542

-0.11 (-0.14%)

Updated Sep 17, 2025 04:00 PM ET

Pre-Market: $76.77 +0.33 (0.43%) 8:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.

Zacks Equity Research

ResMed (RMD) Q3 Earnings to Gain From Growing Ventilator Sales

by Zacks Equity Research

ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.

Zacks Equity Research

Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.

Zacks Equity Research

Cerner (CERN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.

Zacks Equity Research

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

Zacks Equity Research

Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline

by Zacks Equity Research

Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.

Zacks Equity Research

Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow

by Zacks Equity Research

On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.

Zacks Equity Research

Align Technology (ALGN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in the first two months of Q1.

Zacks Equity Research

Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare Stock Now

by Zacks Equity Research

NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.

Zacks Equity Research

Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?

by Zacks Equity Research

LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.

Zacks Equity Research

Here's Why You Should Hold on to HMS Holdings Stock Now

by Zacks Equity Research

HMS Holdings (HMSY) continues to benefit from strong PI solutions and TPM. However, stiff competition remains a concern.

Nalak Das headshot

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

by Nalak Das

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Zacks Equity Research

Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

by Zacks Equity Research

Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.

Zacks Equity Research

Masimo Collaborates With Samsung to Help Fight Coronavirus

by Zacks Equity Research

Masimo (MASI) and Samsung Electronics America collaborate to bring Masimo SafetyNet Patient App on the latter's select smartphones for faster distribution of Masimo SafetyNet to COVID-19 patients.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, margin contraction remains a woe.

Zacks Equity Research

Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?

by Zacks Equity Research

Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.

Zacks Equity Research

DexCom (DXCM) Jumps: Stock Rises 5.6%

by Zacks Equity Research

DexCom (DXCM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Sriparna Ghosal headshot

Here's Why You Should Retain Accuray in Your Portfolio

by Sriparna Ghosal

Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.

Zacks Equity Research

Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) successfully attains EUA from the FDA as well as receives the CE Mark in Europe for its COVID-19 diagnostic test.

Sriparna Ghosal headshot

3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1

by Sriparna Ghosal

Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.

Zacks Equity Research

Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Intuitive Surgical (ISRG) first-quarter results benefit from strong growth across all businesses and higher revenues.

Zacks Equity Research

Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance

by Zacks Equity Research

Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.

Zacks Equity Research

Here's Why You Should Retain OPKO Health in Your Portfolio

by Zacks Equity Research

Investor confidence remains high in OPKO Health's (OPK) stock, thanks to solid prospects.